Syntax Bio Secures $14.4 Million in Series A Funding
Syntax Bio, a company specializing in synthetic biology to develop next-generation cell therapies, has successfully raised $14.4 million in a Series A funding round. This funding will support the ongoing development of its proprietary Cellgorithm platform, which utilizes a CRISPR-based system to enhance stem cell differentiation. The funds will also aid in advancing the company's pancreatic beta cell therapy program aimed at treating type 1 diabetes.
Investors and Funding Details
The Series A round saw participation from a diverse group of investors including Astellas Venture Management, Illumina Ventures, DCVC Bio, and Civilization Ventures, among others. New investors joining this round are Draper Associates, Allegis Capital, LongGame, Mayo Clinic, and several others. The absence of a lead investor highlights the collaborative nature of this funding effort.
Leadership Changes
Alongside the funding announcement, Syntax Bio has made several key leadership appointments. Ryan Clarke, co-founder of the company, has transitioned from Chief Technology Officer to Chief Scientific Officer, focusing on scientific strategy and stem cell therapy innovation. Nikolas Balanis, another co-founder, has been promoted to Chief Technology Officer, where he will lead the development of the company's synthetic biology platform and AI-driven computational biology capabilities. Both Clarke and Balanis will report to John Craighead, who became the CEO in 2025.
The company also strengthened its board of directors with the addition of Doug Doerfler, a seasoned biotechnology entrepreneur, and Pete Bodine, Managing Director at Allegis Capital. Additionally, Melissa Carpenter and Everett Meyer have joined the scientific advisory board, bringing extensive experience in stem cell biology and regenerative medicine.
Use of Funds
The newly acquired funds are earmarked for further development of the Cellgorithm platform and to push forward the pancreatic beta cell therapy program through preclinical proof of concept. This strategic investment aims to bolster the company's capabilities in addressing type 1 diabetes.
Conclusion
With this substantial Series A funding, Syntax Bio is well-positioned to make significant strides in the field of cell therapy. The financial backing, coupled with strategic leadership changes, sets the stage for the company's future developments and potential breakthroughs in synthetic biology and regenerative medicine.